en · de · es · pt
lab-handbook.peptides5388.com › Wiki › Sr9009 Background And Mechanism — Complete Guide

Sr9009 Background And Mechanism — Complete Guide

By Editorial Desk · published 2025-07-15 · last reviewed 2025-08-15 · Wiki

REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-08-15. Numbers and descriptions here follow the published literature rather than marketing material.

SR9009 Background and Mechanism

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

SR9009 Handling and Quality Control

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

Analytical Detection and Laboratory Handling

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Related pages on this site

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Notes from published material

=== Domestic === Syria: Syria condemned the Israeli strikes on Syria and asserted their right to self-defense. The foreign ministry said that Israel's "flagrant assault, which forms part of a deliberate policy pursued by the Israeli entity to inflame tensions, spread chaos, and undermine security and stability in Syria, constitutes a blatant violation of the United Nations Charter and international humanitarian law". The head of security in Suwayda, Suleiman Abdul Baqi, declared "that some of the Druze in Israel who misled Hikmat al-Hijri into believing he would be granted a "state" have no influence in Washington" and "the American administration supports President Ahmed al-Sharaa and a unified Syrian state, and is against any separatist project or separatist groups, and does not support any Syrian component except through sending humanitarian aid, and supports the security and stability of Syria". Rojava/DAANES: The SDF condemned the violence in Suwayda, commenting on the civilian casualties in the conflict. The Kurdish women-led YPJ in particular expressed its readiness to "protect Druze women and civilians, [and to] shoulder all the responsibility placed upon us without hesitation". On 17 July 2025 the Social Affairs and Labor Authority of the DAANES dispatched humanitarian aid to Suwayda Governorate. Suwayda Military Council: An official statement was issued declaring a state of maximum alert. The council announced that all combat units under its command had been placed on maximum alert, prepared for immediate intervention if deemed necessary to protect civilians.

=== Location === The company moved from 3200 Hillview Ave to the former headquarters of Facebook at 1601 S. California Ave in June 2012. By 2017 Theranos was headquartered at 1701 Page Mill Road, Palo Alto, California, paying a $1 million per month lease for the Stanford Research Park building. It had laboratories in Newark, California, and Scottsdale, Arizona. In 2017, when Theranos was still denying its publicly reported fraud, the company vacated its Page Mill headquarters, moving remaining staff into the Newark, California, laboratories; Stanford University School of Medicine converted the Page Mill building to offices and medical laboratories.

== External links == WHO fact sheet on opioid overdose Community management of opioid overdose (PDF). World Health Organization. 2014. ISBN 978-92-4-154881-6. Archived from the original (PDF) on 1 September 2022.

Physiologically based pharmacokinetic (PBPK) modeling is a mathematical modeling technique for predicting the absorption, distribution, metabolism and excretion (ADME) of synthetic or natural chemical substances in humans and other animal species. PBPK modeling is used in pharmaceutical research and drug development, and in health risk assessment for cosmetics or general chemicals. PBPK models strive to be mechanistic by mathematically transcribing anatomical, physiological, physical, and chemical descriptions of the phenomena involved in the complex ADME processes. A large degree of residual simplification and empiricism is still present in those models, but they have an extended domain of applicability compared to that of classical, empirical function based, pharmacokinetic models. PBPK models may have purely predictive uses, but other uses, such as statistical inference, have been made possible by the development of Bayesian statistical tools able to deal with complex models. That is true for both toxicity risk assessment and therapeutic drug development. PBPK models try to rely a priori on the anatomical and physiological structure of the body, and to a certain extent, on biochemistry. They are usually multi-compartment models, with compartments corresponding to predefined organs or tissues, with interconnections corresponding to blood or lymph flows (more rarely to diffusions).

Umami ( from Japanese: うま味, pronounced [ɯmami]), or savoriness, is one of the five basic tastes. It is characteristic of broths and cooked meats. People taste umami through taste receptors that typically respond to glutamates and nucleotides, which are widely present in meat broths and fermented products. Glutamates are commonly added to some foods in the form of monosodium glutamate (MSG), and nucleotides are commonly added in the form of disodium guanylate, inosine monophosphate (IMP) or guanosine monophosphate (GMP). Since umami has its own receptors rather than arising out of a combination of the traditionally recognized taste receptors, scientists now consider umami to be a distinct taste. Food, beverages, or condiments that have a strong umami flavor include meats, shellfish, fish (including fish sauce and preserved fish such as Maldives fish, katsuobushi, sardines, and anchovies), dashi, tomatoes, mushrooms, hydrolyzed vegetable protein, meat extract (Bouillon cubes), yeast extract (beer, Marmite, Vegemite), kimchi, cheeses (Parmesan, Asiago cheese, or blue cheese), as well as sauces such as A1 sauce, Worcestershire sauce, and soy sauce. In 1908, Kikunae Ikeda of the University of Tokyo scientifically identified umami as a distinct taste attributed to glutamic acid. As a result, in 1909, Ikeda and Saburōsuke Suzuki founded Ajinomoto Co., Inc.

Sources: en.wikipedia.org

Further detail

A root canal is the naturally occurring anatomic space within the root of a tooth. It consists of the pulp chamber (within the coronal part of the tooth), the main canal(s), and more intricate anatomical branches that may connect the root canals to each other or to the surface of the root.

Homocysteine is biosynthesized naturally via a multi-step process. First, methionine receives an adenosine group from ATP, a reaction catalyzed by S-adenosyl-methionine synthetase, to give S-adenosyl methionine (SAM). SAM is a widely used source of methyl radicals and a cofactor for radical SAM enzymes. Transfer of the methyl group to an acceptor molecule results in the formation of S-adenosyl-homocysteine. Hydrolysis of this thioether gives L-homocysteine. L-Homocysteine reacts with tetrahydrofolate (THF) to give L-methionine.

(1986) Lipids, 21, 170-174). An example of the latter is the introduction of bioactive compounds into the mammary gland by infusion through the streak canal (Patton, S. (1974) EBS Lett., 48, 85-87). This idea spawned a series of papers from several investigators on the cellular mechanism of milk secretion and opens up the possibility of genetically modifying the mammary gland by the in vivo transfection of mammary epithelial cells with recombinant DNA."

== Morphology == An animal's hump is formed by neural spines on the thoracic vertebrae. Despite only being known from the fossil record, the woolly mammoth and species of the genus Titanotylopus are assumed to have had humps due to the presence of such spines in their skeletons. In the gaur, the hump is formed solely because of the skeletal structure, as its third to eleventh vertebrae have such spines. In both dromedaries and bactrian camels, humps are attached to the adipose tissue in the dorsal region, and fixed in place by the trapezius and rhomboid muscles.

=== Biomarker === A multi-locus genetic risk score study based on a combination of 27 loci including the PCSK9 gene, identified individuals at increased risk for both incident and recurrent coronary artery disease events, as well as an enhanced clinical benefit from statin therapy. The study was based on a community cohort study (the Malmo Diet and Cancer study) and four additional randomized controlled trials of primary prevention cohorts (JUPITER and ASCOT) and secondary prevention cohorts (CARE and PROVE IT-TIMI 22).

Sources: en.wikipedia.org

Supporting material

Compared to the City of Toronto as a whole, industry in the district is similar in all labour force categories, save for manufacturing which is higher in the district, and professional, scientific and technical services which are lower. Notable companies that have their headquarters in the district include Toyota Canada, Owens Corning (Toronto), Elizabeth Grant International, Enterprise Holdings, Inc., Thomson Carswell, Bell Media, Teva Canada, Cinram, Royal Doulton, SKF, Amphenol, Dart Canada, Mastermind Toys, Alfa Laval, President's Choice Financial, Aviva, Yellow Pages Group, Telus, and Lee Kum Kee Canada. The pizza chains 241 Pizza and Pizza Nova have their headquarters in Scarborough. Amazon opened a new fulfillment centre in north Scarborough in 2020. Large companies that have moved out of Scarborough include: General Motors Canada Van Assembly plant (1993) and Eli Lilly Canada (2019). A high-density business district has been built up in Scarborough City Centre. Points of interest in the area include Scarborough Town Centre, Albert Campbell Square, Street Eats Market, many surrounding stores, and government and business offices. The area has become one of Toronto's secondary business districts outside of Downtown Toronto.

On August 23, 1879, 26 members of the Christian Scientists' Association were granted a charter to form the Church of Christ (Scientist). Services were held in people's homes in Lynn and later in Hawthorne Hall, Boston. On January 31, 1881, Eddy was granted a charter to form the Massachusetts Metaphysical College to teach "pathology, ontology, therapeutics, moral science, metaphysics, and their application to the treatment of disease." The college lived wherever Eddy did; a new sign appeared on 8 Broad Street. In October 1881 there was a revolt. Eight church members resigned, signing a document complaining of Eddy's "frequent ebullitions of temper, love of money, and the appearance of hypocrisy." Only a few students remained, including Calvin Frye, who became Eddy's most loyal personal assistant. They appointed Eddy pastor of the church in November 1881, and drew up a resolution in February 1882 that she was "the chosen messenger of God to the nations." Despite the support, the resignations ended Eddy's time in Lynn. The church was struggling and her reputation had been damaged by the disputes. By now 61 years old, she decided to move to Boston, and in early 1882 rented a house at 569 Columbus Avenue, a silver plaque announcing the arrival of the Massachusetts Metaphysical College.

Saline breast prosthesis filled with sterile saline solution. Silicone breast prosthesis filled with viscous silicone gel. Alternative-composition breast prosthesis filled with various fillers (soy oil, polypropylene string); now discontinued. Structured breast prosthesis constructed of nested shells, made of elastomer silicone, with saline solution filling the space between the silicone shells; now discontinued.

Ecdysozoa () is a group of protostome animals, including Arthropoda (insects, chelicerates (including arachnids), crustaceans, and myriapods), Nematoda, and several smaller phyla. The grouping of these animal phyla into a single clade was first proposed by Eernisse et al. (1992) based on a phylogenetic analysis of 141 morphological characters of ultrastructural and embryological phenotypes. This clade, that is, a group consisting of a common ancestor and all its descendants, was formally named by Aguinaldo et al. in 1997, based mainly on phylogenetic trees constructed using 18S ribosomal RNA genes. A large study in 2008 by Dunn et al. strongly supported the monophyly of Ecdysozoa. The group Ecdysozoa is supported by many morphological characters, including growth by ecdysis, with moulting of the cuticle – without mitosis in the epidermis – under control of the prohormone ecdysone, and internal fertilization. The group was initially contested by a significant minority of biologists. Some argued for groupings based on more traditional taxonomic techniques, while others contested the interpretation of the molecular data.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network